The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study
Abstract
Objective: This study aimed to compare the effects of insulin pump intensive therapy alone with those of insulin pump intensive therapy combined with metformin or dapagliflozin on the time to achieve glycemic targets, total insulin dose at the end of intensive therapy, and pancreatic function. The study aimed to understand the impact of adding the traditional antidiabetic drug metformin and the novel antidiabetic drug dapagliflozin to routine intensive insulin therapy on treatment outcomes.
Methods: A total of 110 patients with newly diagnosed T2DM (with glycated hemoglobin >9%, fasting blood glucose >11.1 mmol/L, or obvious symptoms of hyperglycemia) were enrolled in a single-center randomized controlled trial. Patients were randomized into three groups. The final analysis included 81 participants (73.6% of the enrolled) with complete data for the primary outcomes, distributed as follows: Group 1 (insulin only, n = 25), Group 2 (insulin plus dapagliflozin, n = 20), and Group 3 (insulin plus metformin, n = 36). The term "newly diagnosed" was defined as a diagnosis confirmed within 1 year prior to enrollment, in accordance with the Chinese guidelines for the prevention and treatment of T2DM. All patients were either treatment-naïve or had not received any sustained glucose-lowering pharmacotherapy for more than 2 weeks since diagnosis. The primary outcomes were the time to achieve glycemic targets, total insulin dose at the end of intensive therapy, and pancreatic function.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 110 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.